Selecta Biosciences, Inc (SELB)

Etorro trading 970x250
Selecta Biosciences, Inc (SELB) Logo

About Selecta Biosciences, Inc

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. Address: 65 Grove Street, Watertown, MA, United States, 02472

Selecta Biosciences, Inc News and around…

Latest news about Selecta Biosciences, Inc (SELB) common stock and company :

The Petri Dish: Selecta hit with clinical hold, Biogen loses patent appeal
02 Dec, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chronic Refractory Gout
01 Dec, 2021 Yahoo! Finance

-DISSOLVE program on track with 12-month study fully enrolled--DISSOLVE II on track for full enrollment in early 2022--Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN, Mass. and STOCKHOLM, Sweden, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI), today announced the completion of enrollment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development program of

56 Biggest Movers From Friday
29 Nov, 2021 FinancialContent

Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been ...

48 Stocks Moving In Friday's Mid-Day Session
26 Nov, 2021 FinancialContent

Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
26 Nov, 2021 FinancialContent

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The ...

Selecta's Gene Therapy Trial For Genetic Metabolic Disorder Put On FDA Hold
26 Nov, 2021 FinancialContent

TheFDA has placed a clinical holdonSelecta Biosciences Inc's(NASDAQ: SELB) Phase 1/2 trial of SEL-302 (which ...

25 Stocks Moving in Friday's Pre-Market Session
26 Nov, 2021 FinancialContent

Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been ...

A Peek Into The Markets: US Stock Futures Tumble Amid COVID-19 Jitters
26 Nov, 2021 FinancialContent

Pre-open movers U.S. stock futures traded lower in early pre-market trade after a new COVID-19 variant was detected in South Africa. ...

5 Stocks To Watch For November 26, 2021
26 Nov, 2021 FinancialContent

Some of the stocks that may grab investor focus today are: Wall Street expects Pinduoduo Inc. (NASDAQ: PDD) to report quarterly ...

12 Health Care Stocks Moving In Thursday's After-Market Session
25 Nov, 2021 FinancialContent

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of ...

Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
25 Nov, 2021 Yahoo! Finance

The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.

Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
24 Nov, 2021 Yahoo! Finance

-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 (wh

First Week of SELB January 2022 Options Trading
19 Nov, 2021 FinancialContent

Investors in Selecta Biosciences Inc (SELB) saw new options begin trading this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SELB options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.

10 Best Biotech Stocks Under $5
14 Nov, 2021 Yahoo! Finance

In this article, we will discuss the 10 best biotech stocks under $5 in 2021. You can skip our detailed analysis of the biotech sector and go directly to the 5 Best Biotech Stocks Under $5. The biotech industry has seen strong growth in terms of funding through venture capitalists, joint ventures, and co-developments in […]

Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
11 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021. Details on the conference can b

Selecta Biosciences's Return On Capital Employed Insights
10 Nov, 2021 FinancialContent

Benzinga Pro data, Selecta Biosciences (NASDAQ:SELB) reported Q3 sales of $24.43 million. Earnings fell to a loss of $1.97 million, ...

Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Tops Revenue Estimates
09 Nov, 2021 Yahoo! Finance

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
09 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...

Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
09 Nov, 2021 Yahoo! Finance

-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline- -Continued execution of multiple preclinical programs toward IND- -Further strengthened leadership team with the appointment of Kevin Tan as CFO- -As of September 30, 2021, Selecta had approximately $1

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform
08 Nov, 2021 FinancialContent

Selecta Biosciences Inc(NASDAQ: SELB)announced top-line resultsfrom the Phase 1 study evaluating the ImmTOR ...

Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy
08 Nov, 2021 Yahoo! Finance

- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies - - Based on these data Selecta intends to rapidly advance its wholly owned gene therapy pipeline, and continue to selectively evaluate gene therapy partnership opportunities utilizing ImmTOR - - Selecta to h

Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
05 Nov, 2021 Yahoo! Finance

WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. Individuals may participate in the l

Sum Up The Parts: BIB Could Be Worth $131
03 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $130.92 per unit.

Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
28 Oct, 2021 Yahoo! Finance

Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Petri Dish: Selecta, Takeda ink $1.1B deal; Moderna ups Africa commitment
28 Oct, 2021 Yahoo! Finance

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
26 Oct, 2021 Yahoo! Finance

Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies. Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases. Under the terms of the collaboration

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
26 Oct, 2021 FinancialContent

Gainers Ocugen (NASDAQ:OCGN) stock increased by 31.15% to $12.25 during Tuesday's pre-market session. The market ...

Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
26 Oct, 2021 Yahoo! Finance

Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases. This partnership leverages the unique platfor

Selecta In-Licenses Rights To IgG Protease Platform
21 Oct, 2021 FinancialContent

Selecta Biosciences Inc(NASDAQ: SELB) hasannounced a strategic licensing agreementto advance a next-generation IgG ...

Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease
21 Oct, 2021 Yahoo! Finance

- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR™ platform with Genovis’ novel IgG protease, Xork, to unlock the full potential of transformative gene therapies and treat certain IgG-mediated autoimmune diseases - - This novel combination has the potential to simultaneously address two of the key hurdles in gene therapy today: pre-existing immunity and the inability to re-dose AAV gene therapies - WATERTOWN, Mass., Oct.

Selecta Biosciences, Inc (SELB) is a NASDAQ Common Stock listed in , ,

970x250